Tarsus officer plans $388K Rule 144 stock sale

An officer of Tarsus Pharmaceuticals has filed a Rule 144 notice to potentially sell 4,564 common shares, a small amount relative to 43.9 million shares outstanding.

Rhea-AI Filing Summary

Tarsus Pharmaceuticals, Inc. (TARS) has a notice under Rule 144 indicating that officer Seshadri Neervannan plans a potential sale of up to 4,564 shares of common stock through Fidelity Brokerage Services LLC. The planned sale relates to shares acquired via restricted stock vesting and an employee stock purchase plan in 2023.

The notice reports an aggregate market value of about $387,940 for these shares and lists 43,882,996 common shares outstanding, providing context for the size of the proposed sale.

Key Figures

Shares to be sold under Rule 144: 4,564 shares Aggregate market value of shares: $387,940 Shares outstanding: 43,882,996 shares +4 more

7 metrics

Shares to be sold under Rule 144 4,564 shares Maximum common shares covered by the Rule 144 notice

Aggregate market value of shares $387,940 Reported value of 4,564 common shares to be potentially sold

Shares outstanding 43,882,996 shares Common shares of Tarsus Pharmaceuticals reported as outstanding

Restricted stock vesting lots 492; 489; 469; 478; 471; 460 shares Six vesting events between March 15 and March 22, 2023

ESPP purchase 1,705 shares Common shares acquired on June 30, 2023 via ESPP

Proposed sale date September 4, 2026 Date associated with the planned Rule 144 sale

Signature date November 12, 2025 Date of signature by authorized representative on the notice

Key Terms

Rule 144, restricted stock vesting, ESPP Purchase, attorney-in-fact

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock vesting financial

"Common | 03/15/2023 | Restricted Stock Vesting | Issuer"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

ESPP Purchase financial

"Common | 06/30/2023 | ESPP Purchase | Issuer"

attorney-in-fact regulatory

"as attorney-in-fact for Seshadri Neervannan"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What does the Form 144 filing mean for Tarsus Pharmaceuticals (TARS)?

The filing reports that an officer, Seshadri Neervannan, may sell up to 4,564 shares of Tarsus Pharmaceuticals common stock under Rule 144. It is a notice of a potential resale of previously acquired shares, not an issuance of new shares by the company.

How many TARS shares are covered by this Rule 144 notice?

The notice covers up to 4,564 shares of Tarsus Pharmaceuticals common stock. These shares come from restricted stock vesting and an Employee Stock Purchase Plan acquisition that occurred in March and June 2023.

What is the reported market value of the TARS shares to be sold?

The filing reports an aggregate market value of approximately $387,940 for the 4,564 shares of Tarsus Pharmaceuticals common stock that may be sold under Rule 144 through Fidelity Brokerage Services LLC.

How large is this potential TARS share sale relative to shares outstanding?

The company reports 43,882,996 common shares outstanding. The Rule 144 notice covers 4,564 shares, which represents a very small portion of the total shares outstanding.

What transactions generated the TARS shares in this Form 144?

The shares were acquired through restricted stock vesting on several dates from March 15–22, 2023, in amounts ranging from 460 to 492 shares per vesting, and through an ESPP purchase of 1,705 shares on June 30, 2023.

Who is the broker for the potential TARS share sale under Rule 144?

The planned Rule 144 sale of up to 4,564 shares of Tarsus Pharmaceuticals common stock is to be executed through Fidelity Brokerage Services LLC, as stated in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 03:36 PM Accepted by SEC EDGAR 09/04/2026 - 03:36 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001827584
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Tarsus Pharmaceuticals, Inc.
SEC File Number	001-39614
Address of Issuer	15440 LAGUNA CANYON ROAD IRVINE CALIFORNIA 92618
Phone	(949) 409-9820
Name of Person for Whose Account the Securities are To Be Sold	Neervannan Seshadri
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	4564	387940.00	43882996	09/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/15/2023	Restricted Stock Vesting	Issuer			492	03/15/2023	Compensation
Common	03/16/2023	Restricted Stock Vesting	Issuer			489	03/16/2023	Compensation
Common	03/17/2023	Restricted Stock Vesting	Issuer			469	03/17/2023	Compensation
Common	03/20/2023	Restricted Stock Vesting	Issuer			478	03/20/2023	Compensation
Common	03/21/2023	Restricted Stock Vesting	Issuer			471	03/21/2023	Compensation
Common	03/22/2023	Restricted Stock Vesting	Issuer			460	03/22/2023	Compensation
Common	06/30/2023	ESPP Purchase	Issuer			1705	06/30/2023	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/04/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/12/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Gary Redman, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Seshadri Neervannan
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)